Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Jeppe Skov, Jens Juul Holst, Jens Peter Gøtze, Jørgen Frøkiær, Jens Sandahl Christiansen

Abstract

The antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1-ANP axis exists in humans is unknown. In this study, we examined 12 healthy young males in a randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a 2-h native GLP1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP1 infusion increased the urinary sodium excretion markedly, there were no significant changes in either proANP or proBNP concentrations. When GLP1 infusion was stopped, sodium excretion declined rapidly. As proANP concentration reflects ANP secretion, our data could not confirm the existence of a GLP1-ANP axis in humans. Especially, the natriuretic effects of GLP1 seem unlikely to be mediated exclusively via ANP.

OriginalsprogEngelsk
TidsskriftEndocrine Connections
Vol/bind3
Udgave nummer1
Sider (fra-til)11-6
Antal sider6
ISSN2049-3614
DOI
StatusUdgivet - 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males'. Sammen danner de et unikt fingeraftryk.

Citationsformater